Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer
- PMID: 32234905
- DOI: 10.21873/anticanres.14171
Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer
Abstract
Background/aim: Triple-negative breast cancer (TNBC) can be divided into subtypes of basal-like (BL), mesenchymal-like (ML), luminal androgen receptor (LAR), and immunomodulatory (IM). The aim of our study was to assess whether there are distinct radiologic features within the different TNBC subtypes and whether this has potential clinical impact.
Patients and methods: Imaging pictures of 135 patients with TNBC were re-evaluated. TNBC subtyping was performed on asservated tumor tissue using a panel of antibodies.
Results: Mammographic margins of LAR-TNBC were more often spiculated (24.3% versus 0-4.1%). BL-TNBC presented more frequent a mass without calcification in mammogram than other subtypes (71.4% versus 48.6-57.9%). In ultrasound, ML and LAR were described more often with smooth borders.
Conclusion: The histopathological subtype of TNBC influences its presentation in ultrasound and mammogram. This can reflect a different growth pattern of the subtypes and may have an impact on the early diagnosis of TNBC.
Keywords: TNBC subtypes; Triple negative breast cancer; breast cancer; clinical imaging; ultrasound.
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Imaging features of triple-negative breast cancers according to androgen receptor status.Eur J Radiol. 2019 May;114:167-174. doi: 10.1016/j.ejrad.2019.03.017. Epub 2019 Mar 21. Eur J Radiol. 2019. PMID: 31005169 Free PMC article.
-
Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.Breast Cancer Res. 2016 Mar 15;18(1):33. doi: 10.1186/s13058-016-0690-8. Breast Cancer Res. 2016. PMID: 26975198 Free PMC article.
-
The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.Breast Cancer Res Treat. 2019 Aug;177(1):67-75. doi: 10.1007/s10549-019-05298-6. Epub 2019 Jun 1. Breast Cancer Res Treat. 2019. PMID: 31154578
-
Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features.J Zhejiang Univ Sci B. 2022 Aug 15;23(8):617-624. doi: 10.1631/jzus.B2200113. J Zhejiang Univ Sci B. 2022. PMID: 35953756 Free PMC article. Review.
-
Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.Genes Genomics. 2020 Dec;42(12):1381-1387. doi: 10.1007/s13258-020-01014-7. Epub 2020 Nov 3. Genes Genomics. 2020. PMID: 33145728 Review.
Cited by
-
Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer.Cancers (Basel). 2022 Dec 30;15(1):233. doi: 10.3390/cancers15010233. Cancers (Basel). 2022. PMID: 36612226 Free PMC article. Review.
-
Early detection of triple-negative breast cancer: evidence of a favourable prognostic impact in a comparative analysis of screen-detected versus symptomatic cases.BMC Cancer. 2025 Apr 18;25(1):730. doi: 10.1186/s12885-025-14067-2. BMC Cancer. 2025. PMID: 40251506 Free PMC article.
-
Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer.Cancers (Basel). 2021 Apr 1;13(7):1642. doi: 10.3390/cancers13071642. Cancers (Basel). 2021. PMID: 33915941 Free PMC article. Review.
-
Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer.Insights Imaging. 2023 Mar 16;14(1):46. doi: 10.1186/s13244-023-01387-9. Insights Imaging. 2023. PMID: 36929229 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous